Sulfadiazine plasma concentrations in women with pregnancy-acquired compared to ocular toxoplasmosis under pyrimethamine
- PDF / 1,048,447 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 98 Downloads / 141 Views
ropean Journal of Medical Research Open Access
RESEARCH
Sulfadiazine plasma concentrations in women with pregnancy‑acquired compared to ocular toxoplasmosis under pyrimethamine and sulfadiazine therapy: a case–control study Ingrid Reiter‑Owona1, Harald Hlobil2, Martin Enders3, Ute Klarmann‑Schulz1,4,5, Barbara Gruetzmacher1, Veronika Rilling3, Achim Hoerauf1,5 and Justus G. Garweg6,7*
Abstract Background: Dosing recommendations for the treatment of pregnancy-acquired toxoplasmosis are empirical and widely based on experimental data. There are no pharmacological data on pregnant women with acute Toxoplasma gondii infection under treatment with pyrimethamine (PY) and sulfadiazine (SA) and our study intends to tighten this gap. Methods: In this retrospective case–control study, we included 89 pregnant women with primary Toxoplasma infection (PT) treated with PY (50 mg first dose, then 25 mg/day), SA (50 mg/kg of body weight/day), and folinic acid (10–15 mg per week). These were compared to a group of 17 women with acute ocular toxoplasmosis (OT) treated with an initial PY dose of 75 mg, thereafter 25 mg twice a day but on the same SA and folinic acid regimen. The exact interval between drug intake and blood sampling and co-medication had not been recorded. Plasma levels of PY and SA were determined 14 ± 4 days after treatment initiation using liquid chromatography–mass spectrometry and compared using the Mann–Whitney U test at a p
Data Loading...
